Spoken Alpha
CytoDyn Inc.
CytoDyn develops leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, for clinical-stage treatment of solid-tumor cancers including colorectal cancer and triple-negative breast cancer, with ongoing Phase II trials and preclinical research into longer-acting formulations.
CytoDyn Inc is a Healthcare company operating in Biotechnology with a $284.0M market cap.
Most recent reported earnings: Q4 FY2026 (Jul 28, 2026).
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add CYDY, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CYDY.
$ curl https://api.spokenalpha.com/v1/companies/CYDYFAQ
Spoken Alpha indexes CYDY's earnings call transcripts at https://spokenalpha.com/companies/CYDY. Each call links to attributed speakers and parsed analyst Q&A. CytoDyn Inc.'s own investor relations page is at https://www.cytodyn.com/investors.
CytoDyn Inc. (CYDY) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 2026-07-28 | $-0.01 | — | — | $0 | — | — | EODHD |
| Q3 FY2026 | 2026-04-28 | $-0.00 | — | — | $0 | — | — | EODHD |
| Q2 FY2026 | 2026-01-27 | $-0.02 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2026 | 2025-09-01 | $-0.00 | $0.00 | — | — | — | — | EODHD |
| Q4 FY2025 | 2025-07-29 | $-0.01 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-04-13 | $-0.00 | — | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-01-13 | $-0.00 | — | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2024-10-14 | $0.02 | — | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2024-08-14 | $-0.02 | — | — | $0 | — | — | EODHD |
| Q3 FY2024 | 2024-04-14 | $-0.01 | — | — | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-01-15 | $-0.01 | — | — | $0 | — | — | EODHD |
| Q1 FY2024 | 2023-10-22 | $-0.01 | $0.00 | — | $0 | — | — | EODHD |
| Q4 FY2023 | 2023-08-29 | $-0.02 | $0.00 | — | $0 | — | — | EODHD |
| Q3 FY2023 | 2023-04-09 | $-0.02 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-01-08 | $-0.03 | $-0.04 | +25.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2022-10-10 | $-0.03 | $-0.05 | +40.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2022-08-14 | $-0.15 | $-0.04 | -100.0% | $3.1M | — | — | EODHD |
| Q3 FY2022 | 2022-04-10 | $-0.05 | $-0.04 | -25.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-01-09 | $-0.05 | $-0.04 | -25.0% | $-1.2M | — | — | EODHD |
| Q1 FY2022 | 2021-10-11 | $-0.05 | $-0.05 | 0.0% | $-1.6M | — | — | EODHD |
Source: EODHD. CYDY reported actuals as published; sparse fields render as —.